CTDH News and Press, Ctd Holdings Inc From 02/26/20

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has completed patient enrollment in its Extension Protocol to the P...

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has completed patient enrollment in its Phase I/II trial to evaluat...

Data cleaning underway, top line results expected the first quarter of 2020 Cyclo Therapeutics, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced tha...

Data show that Trappsol ® Cyclo™, the Company’s proprietary hydroxypropyl beta cyclodextrin drug, reduces levels of trapped cholesterol in liver tissue of Niemann-Pick Disease Type C Patients Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology compa...

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that N. Scott Fine, Chairman and Chief Executive Officer, and o...

Worldwide will serve as CRO for the Company’s Clinical Programs Evaluating Trappsol ® Cyclo™ for the Treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cy...

ORLANDO, FL / ACCESSWIRE / December 18, 2019 / Cyclo Therapeutics, Inc. (OTCQB:CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, received a buy recommendation and $1.25 price target from ThinkEquity, a division of Fordham Fi...

Data show that Trappsol ® Cyclo™, the Company’s proprietary hydroxypropyl beta cyclodextrin drug, reduces levels of trapped cholesterol in liver tissue of Niemann-Pick Disease Type C Patients Cyclo Therapeutics, Inc. (OTCQB:CTDH), a clinical-stage biotechnology compan...

AdaptHealth (NASDAQ: AHCO ) initiated with Outperform rating and $13 (30% upside) price target at SVB Leerink. More news on: AdaptHealth Corp., CryoLife, Inc., Acadia Healthcare Company, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

ORLANDO, Fla / ACCESSWIRE / December 10, 2019 / Sharon H. Hrynkow, Ph.D., Chief Scientific Officer of Cyclo Therapeutics (OTCQB: CTDH), was appointed to the President's Council of Advisors on Science and Technology (PCAST) in October. Dr. Hrynkow, a neuroscientist by training, has served in...